# ADV-101

Source: https://onco.cc/drugs/adv-101/  
OnCo record `adv-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADV-101 is an experimental antibody-drug conjugate from Advesya, at a stage the company does not state for cancer.

## Summary

ADV-101 is an antibody-drug conjugate (humanised IgG1, cleavable linker, topoisomerase I inhibitor payload) from Advesya. A first-in-class antibody-drug conjugate: a humanised IgG1 antibody to IL-1RAP joined by a cleavable linker to a topoisomerase I inhibitor, released inside IL-1RAP-expressing cells after internalisation, with bystander killing nearby. The company does not state its stage; it is aimed at cancer. No clinical trial naming it is registered on ClinicalTrials.gov. The company gives no stage for ADV-101 and no registered trial was found (searched ADV-101, IL1RAP, IL-1RAP, Advesya); preclinical is inferred from the absence of a trial. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Tags: pipeline
- Code: ADV-101
- Modality: Antibody-drug conjugate (humanised IgG1, cleavable linker, topoisomerase I inhibitor payload)
- Mechanism: A first-in-class antibody-drug conjugate: a humanised IgG1 antibody to IL-1RAP joined by a cleavable linker to a topoisomerase I inhibitor, released inside IL-1RAP-expressing cells after internalisation, with bystander killing nearby.

## Sources

- Advesya: advesya.com: https://advesya.com/our-science/
- Advesya: advesya.com: https://advesya.com/our-science/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Advesya](https://onco.cc/companies/advesya/)

---
JSON: https://onco.cc/api/v1/entities/adv-101.json